---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-095460"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2026-08-13T11:25:27+00:00"
generated_at: "2026-08-13T11:30:16.502389+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cellectar Q2 net loss $6.9M; cash $34M; Phase 3 iopofosine trial site activation started

## Summary
- Net loss $6.9M ($0.57/share) vs $5.4M ($3.39/share) in Q2 2025; R&D up to $4.6M from $2.4M.
- Cash $34.0M at June 30, 2026 vs $13.2M at Dec 31, 2025; funded into Q2 2027.
- Initiated site activation for confirmatory Phase 3 iopofosine I 131 in WM; NDA planned mid-2027 under accelerated approval.
- Dosed first patients in Phase 1b CLR 125 for triple-negative breast cancer.
- May 2026 financing: ~$35M upfront, up to $105M milestone-based securities to fund Phase 3.

## SEC filing metadata
- accession: 0001104659-26-095460
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2026-08-13T11:25:27+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465926095460/0001104659-26-095460-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465926095460/tm2623056d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-095460
- JSON: https://secwatch.observer/filing/0001104659-26-095460.json
- Plain text: https://secwatch.observer/filing/0001104659-26-095460.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.